Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients.

Zhi-Li Jin,Tao He,Li Peng,Xiao-Yan Wu,Di Fan,Ming Chen,Yong-Zhen Fan,Yuan-Lin Guo,Zhi-Bing Lu,Hai-Rong Wang

Current medical science（2023）

引用 0|浏览9

暂无评分

摘要

The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a) levels in ACS CHIPs-PCI. However, further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.

查看译文

关键词

PCSK9 inhibitor, complex higher-risk and indicated patients, lipoprotein(a) level, low-density lipoprotein cholesterol level, 2-year cardiovascular event rate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要